ArticlePloS one2016
Burden of Liver Disease among Community-Based People Who Inject Drugs (PWID) in Chennai, India.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- The Dual Burden of Hepatitis B and C Among Drug Users in Asia: The First Systematic Review and Meta-Analysis.Pathogens (Basel, Switzerland) · 2025Pooled it
- HIV, hepatitis B & C in people who inject drugs in India: A systematic review of regional heterogeneity & overview of opioid substitution treatment.The Indian journal of medical research · 2023Pooled it
- Directly observed therapy of sofosbuvir/ribavirin +/- peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT).Journal of viral hepatitis · 2018Trial
- Barriers to and impacts of hepatitis C treatment among people who inject drugs in Kenya: A qualitative study.PLOS global public health · 2025Article
- Movement Disorders and Liver Disease.Movement disorders clinical practice · 2021Review
- High dropout rate from aftercare program of antihepatitis C therapy for patients with history of injection drug use.JGH open : an open access journal of gastroenterology and hepatology · 2020Article
- Systematic Review and Meta-Analysis of Global Prevalence of HBsAg and HIV and HCV Antibodies among People Who Inject Drugs and Female Sex Workers.Pathogens (Basel, Switzerland) · 2020Review
- Risk of Hepatitis E among Persons Who Inject Drugs in Hong Kong: A Qualitative and Quantitative Serological Analysis.Microorganisms · 2020Article
- Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: Analysis of a global dataset.Journal of hepatology · 2019Article
- Comparison of the prevalence, severity, and risk factors for hepatic steatosis in HIV-infected and uninfected people.BMC gastroenterology · 2019Observational
- Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India.The International journal on drug policy · 2018Article
- Current Scenario of Hepatitis B and Its Treatment in India.Journal of clinical and translational hepatology · 2017Review
- Hepatitis C treatment: where are we now?International journal of general medicine · 2017Review
- Serum Fibrosis Markers for the Diagnosis of Liver Disease Among People With Chronic Hepatitis C in Chennai, India.Open forum infectious diseases · 2016Article
- Morbidity and Mortality Among Community-Based People Who Inject Drugs With a High Hepatitis C and Human Immunodeficiency Virus Burden in Chennai, India.Open forum infectious diseases · 2016Article
- Prevalence of hepatitis B and C markers in blood donors deferred from donating blood due to hepatitis-related risk factors.Asian journal of transfusion scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
BACKGROUND AND
objectiveWe characterize the burden of liver disease in a cohort of PWID in Chennai, India, with a high prevalence of HCV. MATERIALS AND
methods1,042 PWID were sampled through community outreach in Chennai. Participants underwent fasting blood draw, questionnaire and an examination that included liver stiffness assessment using transient elastography (Fibroscan) and assessment of steatosis via ultrasound.
resultsThe median age was 39 years, all were male, 14.8% were HIV infected and 35.6% were HCV antibody positive, of whom 78.9% were chronically infected (HCV RNA positive). Median liver stiffness was 6.2 kPA; 72.9% had no evidence of or mild stiffness, 14.5% had moderate stiffness, and 12.6% had evidence of severe stiffness/cirrhosis. Prevalence of severe stiffness/cirrhosis was significantly higher among persons who were older, had a longer duration of injecting drugs, higher body mass index, higher prevalence of insulin resistance, higher prevalence of steatosis, higher HCV RNA levels and evidence of alcohol dependence. An estimated 42.1% of severe stiffness/cirrhosis in this sample was attributable to HCV. 529 (53.0%) had some evidence of steatosis. Prevalence of steatosis was higher among those who had larger waist circumference, insulin resistance, higher HDL cholesterol and a history of antiretroviral therapy.
conclusionsWe observed a high burden of liver disease in this relatively young cohort that was primarily driven by chronic HCV infection, metabolic factors (insulin resistance and steatosis) and heavy alcohol use. Interventions to improve access to HCV treatment and reduce alcohol use are needed to prevent further progression of liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.